Sartane

Sartane is a term encountered in some medical and pharmaceutical contexts to refer to the class of drugs known in English as angiotensin II receptor blockers (ARBs). The name is associated with the common drug-ending -sartan, and in several languages the singular form Sartane may be used to denote either an individual ARB or the class as a whole.

ARBs selectively block the angiotensin II type 1 receptor (AT1). By inhibiting this receptor, sartanes prevent vasoconstriction, aldosterone release, and sodium retention, leading to lower blood pressure and reduced cardiovascular workload. They are typically prescribed when treatment with other antihypertensives is insufficient or not tolerated.

Common indications include hypertension, heart failure with reduced ejection fraction, and protection of kidney function in diabetic nephropathy or other proteinuric kidney diseases. They can also be used after myocardial infarction in certain patients, especially when ACE inhibitors are unsuitable.

Representative members of this class include losartan, valsartan, candesartan, irbesartan, olmesartan, telmisartan, and eprosartan. While pharmacologic profiles differ, all ARBs share the same general mechanism and therapeutic aims.

Safety and tolerability are favorable for many patients, but sartanes can cause dizziness and hyperkalemia. They have a lower risk of cough and angioedema than ACE inhibitors. They are contraindicated in pregnancy. Drug interactions include potential kidney effects with NSAIDs and increased hyperkalemia risk when used with potassium-sparing agents or supplements.

In English-language sources the class is usually called ARBs or sartans; Sartane appears mainly in non-English references as the singular or as a regional naming convention.